S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

$5.15
+0.14 (+2.79%)
(As of 03/27/2024 ET)
Today's Range
$4.97
$5.21
50-Day Range
$4.89
$5.95
52-Week Range
$4.82
$9.06
Volume
2.61 million shs
Average Volume
3.34 million shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.29

BioCryst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
158.0% Upside
$13.29 Price Target
Short Interest
Bearish
14.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
0.64mentions of BioCryst Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.62) to ($0.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.75 out of 5 stars

Medical Sector

270th out of 939 stocks

Biological Products, Except Diagnostic Industry

32nd out of 153 stocks

BCRX stock logo

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX Stock Price History

BCRX Stock News Headlines

BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 4.7%
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
BCRX Apr 2024 6.000 put
BCRX Apr 2024 6.000 call
BCRX Apr 2024 9.000 call
BCRX Apr 2024 7.000 put
BCRX Apr 2024 7.000 call
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
BCRX Apr 2024 5.000 put
Analysts’ Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)
Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call
BioCryst Pharmaceuticals reports Q4 results
A Preview Of BioCryst Pharma's Earnings
See More Headlines
Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/27/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCRX
CUSIP
09058V10
Employees
536
Year Founded
1986

Price Target and Rating

Average Stock Price Target
$13.29
High Stock Price Target
$30.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+158.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-226,540,000.00
Pretax Margin
-68.26%

Debt

Sales & Book Value

Annual Sales
$331.41 million
Book Value
($2.22) per share

Miscellaneous

Free Float
197,079,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
1.92

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

BCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings
or view top-rated stocks.

What is BioCryst Pharmaceuticals' stock price target for 2024?

7 equities research analysts have issued 1 year target prices for BioCryst Pharmaceuticals' stock. Their BCRX share price targets range from $10.00 to $30.00. On average, they expect the company's stock price to reach $13.29 in the next twelve months. This suggests a possible upside of 158.0% from the stock's current price.
View analysts price targets for BCRX
or view top-rated stocks among Wall Street analysts.

How have BCRX shares performed in 2024?

BioCryst Pharmaceuticals' stock was trading at $5.99 at the beginning of the year. Since then, BCRX stock has decreased by 14.0% and is now trading at $5.15.
View the best growth stocks for 2024 here
.

When is BioCryst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our BCRX earnings forecast
.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings data on Monday, February, 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.04. The biotechnology company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $89.19 million.

What ETFs hold BioCryst Pharmaceuticals' stock?
What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

What other stocks do shareholders of BioCryst Pharmaceuticals own?
Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.67%), Vanguard Group Inc. (8.62%), Avoro Capital Advisors LLC (6.37%), Braidwell LP (2.79%), Kynam Capital Management LP (2.25%) and Nuveen Asset Management LLC (1.69%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Machelle Sanders, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends
.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners